Trimethylamine-N-oxide is an independent risk factor for hospitalization events in patients receiving maintenance hemodialysis

References

• Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med. 2006;354:997–999.
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351:1296–1305.
   PubMed Web of Science ®Google Scholar
• Mansuri U, Patel AA, Dave M, et al. Impact of dialysis requirement in community-acquired pneumonia hospitalizations. Cureus. 2018;10:e3164.
   PubMed Web of Science ®Google Scholar
• Syed-Ahmed M, Narayanan M. Immune dysfunction and risk of infection in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26:8–15.
   PubMed Web of Science ®Google Scholar
• Bacci M, Russo F, Carvalho G, et al. Endoscopic alterations in a cohort of hemodialysis patients: a cross-sectional study. Int J Gen Med. 2014;7:459–461.
   PubMedGoogle Scholar
• Kahn MR, Robbins MJ, Kim MC, et al. Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol. 2013;10:261–273.
   PubMed Web of Science ®Google Scholar
• Schocken DD, Benjamin EJ, Fonarow GC, et al.; Functional Genomics and Translational Biology Interdisciplinary Working Group. American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; Functional Genomics and Translational Biology Interdisciplinary Working Group. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008;117:2544–2565.
   PubMed Web of Science ®Google Scholar
• Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25:657–670.
   PubMed Web of Science ®Google Scholar
• Kaysen GA, Johansen KL, Chertow GM, et al. Associations of trimethylamine N-oxide with nutritional and inflammatory biomarkers and cardiovascular outcomes in patients new to dialysis. J Ren Nutr. 2015;25:351–356.
   PubMed Web of Science ®Google Scholar
• Tang WH, Wang Z, Shrestha K, et al. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J Card Fail. 2015; 21:91–96.
   PubMed Web of Science ®Google Scholar
• Gregory JC, Buffa JA, Org E, et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem. 2015; 290:5647–5660.
   PubMed Web of Science ®Google Scholar
• Wang Z, Tang WH, Buffa JA, et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J. 2014; 35:904–910.
   PubMed Web of Science ®Google Scholar
• Tilg H. A Gut Feeling about Thrombosis. N Engl J Med. 2016; 374:2494–2496.
   PubMed Web of Science ®Google Scholar
• Ierardi E, Sorrentino C, Principi M, et al. Intestinal microbial metabolism of phosphatidylcholine: a novel insight in the cardiovascular risk scenario. Hepatobiliary Surg Nutr. 2015; 4:289–292.
   PubMed Web of Science ®Google Scholar
• Kim RB, Morse BL, Djurdjev O, et al.; CanPREDDICT Investigators. Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. Kidney Int. 2016;89:1144–1152.
   PubMed Web of Science ®Google Scholar
• Shafi T, Powe NR, Meyer TW, et al. Trimethylamine N-oxide and cardiovascular events in hemodialysis patients. J Am Soc Nephrol. 2017;28:321–331.
   PubMed Web of Science ®Google Scholar
• Stubbs JR, Stedman MR, Liu S, et al. Trimethylamine N-oxide and cardiovascular outcomes in patients with ESKD receiving maintenance hemodialysis. Clin J Am Soc Nephrol. 2019;14:261–267.
   PubMed Web of Science ®Google Scholar
• Habach G, Bloembergen WE, Mauger EA, et al. Hospitalization among United States dialysis. patients: hemodialysis versus peritoneal dialysis. J Am Soc Nephrol. 1995;5:1940–1948.
   PubMedGoogle Scholar
• Tang WH. Trimethylamine N-oxide as a novel therapeutic target in CKD. J Am Soc Nephrol. 2016;27:8–10.
   PubMed Web of Science ®Google Scholar
• Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57–63.
   PubMed Web of Science ®Google Scholar
• Rhee EP, Clish CB, Ghorbani A, et al. A combined epidemiologic and metabolomic approach improves CKD prediction. JASN. 2013;24:1330–1338.
   Web of Science ®Google Scholar
• Stubbs JR, House JA, Ocque AJ, et al. Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. JASN. 2016;27:305–313.
   Web of Science ®Google Scholar
• Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575–1584.
   PubMed Web of Science ®Google Scholar
• EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482–2494.
   PubMed Web of Science ®Google Scholar
• Chhibber-Goel J, Singhal V, Parakh N, et al. The metabolite trimethylamine-N-oxide is an emergent biomarker of human health. Curr Med Chem. 2017;24:3942–3953.
   PubMed Web of Science ®Google Scholar
• Li P, Zhong C, Li S, et al. Plasma concentration of trimethylamine-N-oxide and risk of gestational diabetes mellitus. Am J Clin Nutr. 2018;108:603–610.
   PubMed Web of Science ®Google Scholar
• Ottiger M, Nickler M, Steuer C, et al. Trimethylamine-N-oxide (TMAO) predicts fatal outcomes in community-acquired pneumonia patients without evident coronary artery disease. Eur J Intern Med. 2016;36:67–73.
   PubMed Web of Science ®Google Scholar
• Guertin KA, Li XS, Graubard BI, et al. Serum trimethylamine N-oxide, carnitine, choline, and betaine in relation to colorectal cancer risk in the alpha tocopherol, beta carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev. 2017;26:945–952.
   PubMed Web of Science ®Google Scholar
• Fennema D, Phillips IR, Shephard EA. Trimethylamine and trimethylamine N-oxide, a flavin-containing monooxygenase 3 (FMO3)-mediated host-microbiome metabolic axis implicated in health and disease. Drug Metab Dispos. 2016;44:1839–1850.
   PubMed Web of Science ®Google Scholar